Photo Credit: Photo by Serge Attal/FLASH90
Street life in Manhattan, New York City

The Israeli start-up Gelesis is in advanced talks with a large pharmaceutical company to develop its pill that makes fat people feel their stomachs are full, resulting in less food intake and a loss in weight.

The pharma company was not identified by Israel’s Globes business newspaper, which said that Gelesis soon will publish results of a recent clinical trial of the pill.

Advertisement




Instead of asking the US Food and Drug Administration (FDA) to consider the product as a nutritional supplement or medical device, the Israeli company wants to offer it is a medicine to increase its market appeal.

The value of the deal with the foreign pharmaceutical company could reach hundreds of millions of dollars. The unidentified company will invest millions of dollars for developing the pill and will pay royalties on sales, Globes added.

The slim-down pill is made from indigestible edible fiber taken before a meal. The pills, after coming in contact with water, inflate and  make food more viscous, keeping it in the stomach longer, and creating the sense of being sated.

A study of the pill’s effects several years ago showed a high rate of those who said they felt they had enough to eat, while only 16 percent reported they suffered side effects of discomfort, which Gelesis may be able to reduce by changing the dosage for certain individuals.

Obesity is a leading cause of death, and the leading treatment for obesity is through surgery.

The obesity treatment market currently includes various appetite suppressants, but the leading solution for morbid obesity is stomach bypass or reduction surgery. Although other products for filling the stomach are under development, Gelesis’ edge is that its product works with food.

A small number of diet drugs are on the market or are being studied by the FDA, but their success has been limited.

Besides Gelesis, at least one other company, EntroMedics, has developed a system to limit the expansion of the stomach and control hunger sensations. However, clinical trials last month were disappointing.

Advertisement

SHARE
Previous articleLocusts Invade Israel but More of a Tourist Site than a Plague
Next articleA Preview of President Obama’s Stage Show to Israel
Tzvi Ben Gedalyahu is a graduate in journalism and economics from The George Washington University. He has worked as a cub reporter in rural Virginia and as senior copy editor for major Canadian metropolitan dailies. Tzvi wrote for Arutz Sheva for several years before joining the Jewish Press.